Guggenheim Reiterates Buy on Monte Rosa Therapeutics, Maintains $28 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.3%

Neg 0% Neu 88.3% Pos 0%

Guggenheim analyst Michael Schmidt reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and maintains $28 price target.